JAK Inhibitor Deal Benchmarks in Dermatology

Median Upfront

$433M

Range: $238M - $620M

Total Deal Value

$2.3B

Range: $1.5B - $3.1B

Royalty Rate

6.7% - 13.4%

Tiered up to 17.4%

Dev Milestones

$380M

Range: $256M - $506M

Model Your Deal

Market Analysis

JAK Inhibitor therapies in dermatology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 jak inhibitor asset in dermatology is $433M, with total deal values reaching $2.3B. Development milestones average $380M, while regulatory milestones contribute $475M.

The dermatology jak inhibitor landscape is characterized by growing competitive intensity as biologics reshape treatment of moderate-to-severe skin diseases. JAK inhibitors, IL-targeted biologics, and novel topical approaches are expanding beyond psoriasis into atopic dermatitis and other indications. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for jak inhibitor dermatology deals range from 6.7% to 13.4% at the base tier, with tiered escalation reaching 10.7%-17.4% on blockbuster sales. Commercial milestones averaging $1.0B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a jak inhibitor dermatology licensing deal?

Based on our analysis, Phase 2 jak inhibitor licensing deals in dermatology average $433M in upfront payments, with a range of $238M to $620M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for jak inhibitor dermatology transactions?

The median total deal value for Phase 2 jak inhibitor assets in dermatology is $2.3B, ranging from $1.5B to $3.1B. This includes development milestones ($380M), regulatory milestones ($475M), and commercial milestones ($1.0B).

What royalty rates are standard for jak inhibitor deals in dermatology?

Base royalty rates for jak inhibitor dermatology transactions range from 6.7% to 13.4%, with tiered escalations reaching 10.7%-17.4% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in jak inhibitor dermatology deals?

JAK Inhibitor dermatology deals allocate approximately 81% of total deal value to milestones. Development milestones ($380M) make up the largest share, followed by commercial milestones ($1.0B) and regulatory milestones ($475M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

JAK Inhibitor Deal Benchmarks in Dermatology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Dermatology

Monoclonal Antibody in Dermatology

JAK Inhibitor in Immunology & Autoimmune

JAK Inhibitor in Gastroenterology

Ready to Calculate Your Deal Terms?